Cascade Investment Advisors, Inc. Eli Lilly & CO Transaction History

Cascade Investment Advisors, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 08, 2024	SELL	$724.87 - $909.04 $25,370 - $31,816	-35 Reduced 9.72%	325 $294,000
Q1 2024 Apr 24, 2024	SELL	$592.2 - $792.28 $15,989 - $21,391	-27 Reduced 6.98%	360 $280,000
Q3 2023 Oct 30, 2023	BUY	$434.7 - $599.3 $168,228 - $231,929	387 New	387 $207,000
Q1 2023 May 10, 2023	BUY	$310.63 - $364.82 $132,017 - $155,048	425 New	425 $145,000
Q1 2022 Apr 11, 2022	BUY	$234.69 - $291.66 $5,867 - $7,291	25 Added 6.25%	425 $121,000
Q2 2018 Jul 31, 2018	BUY	$75.7 - $86.88 $30,280 - $34,752	400 New	400 $34.1 Million

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Cascade Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Cascade Investment Advisors, Inc. with notifications on news.